To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monotherapy. 
potential to provide more rapid, greater and sustained reductions in HbA1c; however, it is not known whether this form of therapy increases the risk of adverse events. Simultaneous intensification with two therapies may have benefits, such as improved adherence, reduced clinical inertia and increased durability, but the safety of such an approach is yet to be established.
In the present study, we report results from a randomized, double-blind, active-controlled trial evaluating the efficacy and safety of triple therapy, with the addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (DAPA) plus the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (SAXA), vs dual therapy, with the addition of the DPP-4 inhibitor sitagliptin (SITA) alone, in patients with type 2 diabetes who are inadequately controlled with MET monotherapy. The objective of this study, which included a short-term 26-week treatment period and a further 26-week extension treatment period, was to assess the efficacy, safety and long-term sustained control of a strategy of adding an early combination of two drugs to MET (triple therapy), compared with the commonly used strategy of adding only one drug (dual therapy).
| MATERIALS AND METHODS

| Study design
This multinational, randomized, double-blind, active-controlled, double-dummy parallel-group phase 3b trial (ClinicalTrials.gov Identifier: NCT02284893) was conducted in Hungary, Mexico, Poland, Romania, South Africa and the USA, in accordance with the principles of the Declaration of Helsinki. The protocol and its amendments were reviewed and approved by an Independent Ethics Committee or Institutional Review Board at each study site, and all patients provided written informed consent.
The study comprised a 2-week screening period, a 2-week lead-in period, an initial 26-week randomized, double-blind treatment period, and an extension 26-week site-blind and patient-blind treatment period ( Figure S1 ). During the lead-in period, patients continued to receive background MET medication (≥1500 mg/d). After completing the lead-in period, eligible patients were randomized (1:1) using an interactive voice-response system to receive a combination of DAPA (10 mg/d) and SAXA (5 mg/d) or SITA (100 mg/d), in addition to their regular MET dose for 26 weeks. After completing the 26-week double-blind treatment period, patients entered the extension 26-week site-and patient-blind treatment period, during which they received the same blinded study treatment as during the initial 26-week period in addition to their regular MET dose. Study sites and patients were blinded to the treatment during the extension period, but the study sponsor's delegate, Bristol-Myers Squibb, was unblinded.
| Patients
Men and women at least 18 years of age, with inadequately controlled type 2 diabetes, defined as HbA1c of 8%-10.5%
(64-91 mmol/mol) at screening were eligible for inclusion in the study if they had undergone stable MET therapy for at least 8 weeks prior to enrolment (≥1500 mg/d) and had received no other antidiabetes agent for more than 14 
| Study assessments
The primary efficacy end point was mean change in HbA1c from base- HbA1c from baseline until Week 52 were compared between treatment groups using the same longitudinal repeated-measures analysis as described above. The proportion of patients achieving HbA1c less than 7% (<53 mmol/mol) at Weeks 26 and 52 were compared between treatment groups using previously published methods. 5, 6 Mean changes from baseline to Weeks 26 and 52 in FPG and total body weight, and urinary glucose: creatinine ratio mean changes from baseline to Week 52 were compared using the same longitudi- (Table 1) . Mean (AESD) baseline HbA1c was 8.8 AE 0.9% (73.0 AE 9.3 mmol/mol). More than 99% of patients in both treatment groups were compliant with the study medication (patients received ≥80% and ≤120% of planned drug doses). The proportion of patients who discontinued the study because of a lack of glycaemic control or who were rescued because of failure to achieve pre-specified glycaemic targets are included in Table 2 DAPA plus SAXA group and nine patients in the SITA group used basal insulin. No patient discontinued the study because of a lack of glycaemic control.
| Efficacy
From baseline levels, systolic blood pressure decreased in the DAPA plus SAXA group and increased in the SITA group at Week 52 (adjusted mean AE SE change, −2.6 AE 0.9 vs +2.5 AE 1.0 mm Hg, respectively) ( Table 2 ). The adjusted difference (95% CI) between treatment groups was −5.1 mm Hg (−7.7, −2.5).
The changes from baseline in hsCRP, BNP and urinary glucose:
creatinine ratio are included in Table 2 . Patients in the DAPA plus SAXA group showed a greater change from baseline in urinary glucose: creatinine ratio than did those in the SITA group (adjusted mean AE SE change, 40.1 AE 2.3 vs −1.1 AE 2.4).
Adjusted mean changes from baseline in fasting serum lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) were small and no clinically meaningful differences between treatment groups were observed, with all lipid values remaining in the normal to borderline ranges up to Week 52 (Table 2 ).
| Safety
Triple therapy with DAPA plus SAXA add-on to MET was generally well tolerated after 52 weeks of treatment; the incidence of AEs in patients receiving triple therapy was similar to that in patients receiving dual therapy with SITA add-on ( Table 3 ). AEs that were determined by the investigator to be related to the study drug were reported by 22 (9.5%) patients in the DAPA plus SAXA group and by 17 (7.4%) patients in the SITA group. Few patients discontinued the study because of AEs (DAPA plus SAXA, 1.7%; SITA, 4.4%) and none of these discontinuations was because of hypoglycaemia. The proportion of patients who experienced SAEs was low in both treatment groups (DAPA plus SAXA, 3.9%; SITA, 5.7%). Of the SAEs reported, none was considered by the investigator to be related to DAPA plus SAXA treatment, and only one SAE, drug hypersensitivity, was reported to be related to SITA treatment. The most common SAEs were pneumonia, endometriosis and osteoarthritis, which were reported for two patients each in the SITA group; no other SAEs were reported more than once in either treatment group. The proportion of patients experiencing genital infections was similar in the DAPA plus SAXA group and the SITA group (3.4% vs 2.2%, respectively). Vulvovaginal mycotic infection was the most common genital infection (DAPA plus SAXA, n = 5 women; SITA, n = 2 women). In the DAPA plus SAXA group, two women experienced vaginal infection; one experienced vulvovaginitis and one experienced vulvovaginal candidiasis. In the SITA group, one woman experienced vulvitis and two men experienced balanoposthitis.
UTIs occurred in 6.5% of patients in the DAPA plus SAXA group and in 3.5% of patients in the SITA group (men, 4.0% vs 1.8%; women, 8.3% vs 5.0%, respectively). Unclassified UTIs were more common in women than in men (DAPA plus SAXA, n = 9 women, n = 1 man; SITA, n = 6 women, n = 1 man). In the DAPA plus SAXA group, one man experienced a fungal UTI, one man experienced prostatitis, one man experienced urethritis and two women experienced cystitis. In the SITA group, one man experienced cystitis. The following conditions were reported as other AEs of special interest; definitions are based on preferred terms in the Standardised Medical Dictionary for Regulatory Activities Queries of cardiac failure.
In the DAPA plus SAXA group, one patient reported an AE of syncope, one patient experienced adenocarcinoma of the colon, two patients reported an AE of peripheral oedema and three patients reported an AE of renal impairment/failure (n = 1, acute kidney injury; n = 1, decreased glomerular filtration rate; n = 1, increased blood creatinine); none of these AEs was deemed by the investigator to be related to the study drug. In the SITA group, seven patients experienced at least one cardiac event (n = 4, peripheral swelling; n = 2, peripheral oedema; n = 1, congestive cardiac failure; n = 1, chronic cardiac failure; n = 1, BNP increased); of these events, only one incidence of peripheral swelling was considered by the investigator to be related to the study drug. In addition, five patients in the SITA group reported AEs potentially related to hypotension, hypovolaemia or dehydration, and one One patient in the SITA group requested to discontinue the study because of suspected diabetic ketoacidosis. No deaths were reported for patients who received treatment during the study.
After 52 weeks, no clinically meaningful differences were observed in adjusted mean percentage change from baseline in fasting serum lipids between treatment groups (Table 2 ).
| DISCUSSION
In this double-blind, double-dummy 52-week trial, we report that an intensification strategy of early triple combination therapy with the addition of DAPA plus SAXA provides significantly greater improvements in glycaemic control than a dual therapy strategy with the addition of SITA alone in patients with inadequately controlled MET-treated type 2 diabetes. These improvements were sustained after 52 weeks and were not associated with an increased risk of hypoglycaemia or other diabetes-specific events, and the overall incidence of AEs was low. Furthermore, the improvement in glycaemic control with DAPA plus SAXA treatment was accompanied by a greater reduction in body weight and systolic blood pressure compared with treatment with SITA.
Therapeutic guidelines recommend treatment intensification through addition of anti-diabetes agents for patients with inadequate glycaemic control with MET. 7 However, dual add-on therapy is rarely used, despite the knowledge that glycaemic control is seldom achieved with single-agent add-ons. The use of single-agent add-ons often leads to long periods of hyperglycaemia, 8 which are associated with increased morbidity. 9 The objective of this study was to evaluate the strategy of adding two anti-hyperglycaemic agents (DAPA plus SAXA) simultaneously compared with the more common approach of adding one agent at a time (SITA) in patients with type 2 diabetes that is uncontrolled by MET. Adding two therapies simultaneously led to more rapid glucose control, which was sustained over 52 weeks, suggesting that there may be underlying improvements in insulin sensitivity and β-cell function. Proportion of patients discontinued because of a lack of glycaemic control or rescued for not achieving pre-specified glycaemic targets, % a n = 42 Values are adjusted mean AE SE unless otherwise specified. Abbreviations: BNP, B-type natriuretic protein; DAPA, dapagliflozin; hsCRP, HDL, high density lipoprotein; high-sensitivity C-reactive protein; LDL, low density lipoprotein; MET, metformin; SAXA, saxagliptin; SBP, systolic blood pressure; SE, standard error; SI units, international system of units; SITA, sitagliptin. a Excluding data after rescue medication. b Number of patients discontinued owing to lack of glycaemic control or rescued for not achieving pre-specified glycaemic targets. c Including data after rescue medication.
plus SAXA group required rescue therapy, indicating that SITA add-on therapy is associated with more rapid increases in HbA1c and FPG over time, and that the efficacy of early triple therapy with DAPA plus SAXA add-on to MET is durable. These improvements in glycaemic control are consistent with those reported in a previous clinical study that investigated the efficacy and safety of DAPA plus SAXA add-on to MET compared with the addition to MET of each agent alone. 16 In separate 52-week studies in patients with inadequately controlled type 2 diabetes, triple therapy with the SGLT2 inhibitor ertugliflozin plus SITA add-on to MET resulted in greater improvements in glycaemic control compared with SITA add-on, 17 and triple therapy with the SGLT2 inhibitor empagliflozin plus the DPP-4 inhibitor linagliptin added to MET significantly reduced HbA1c levels compared with the individual drugs added to MET. 18 Together, these studies indicate that a treatment strategy with early combination therapy may result in more rapid and more durable glycaemic control, with no increase in AEs, than single-agent sequential add-on therapy in patients with type 2 diabetes that is inadequately controlled with MET. The proportion of patients experiencing AEs and hypoglycaemia was similar for treatment with DAPA plus SAXA add-on and for treatment with SITA addon therapies. The incidence of genital infections was low and similar between treatment groups; the incidence of UTIs was slightly higher in both men and women with triple therapy than with dual therapy (men, 4.0% vs 1.8%; women, 8.3% vs 5.0%, respectively). The overall incidence of both genital infections and UTIs after 52 weeks was only slightly higher than that observed at 26 weeks, were only mild or moderate in severity, and were similar to those previously reported for DAPA. 19, 20 Triple therapy with DAPA plus SAXA add-on to MET was associated with cumulative weight loss from 26 to 52 weeks, which was greater than that with dual therapy with SITA add-on.
A limitation of the present study is that the effect of dual add-on therapy with DAPA plus SAXA was compared with that of single add-on of a different DPP-4 inhibitor, SITA, and that there were no comparisons with single add-on therapy with DAPA. However, this approach was used to indicate the effects of early combination therapy, rather than sequential add-on therapy, on glycaemic control in patients with high baseline HbA1c levels. Studies have shown that SAXA and SITA have comparable efficacy when added to MET as monotherapy, 21 which suggests that their respective use in the triple and dual therapy arms is unlikely to have had a large effect on the overall change in HbA1c. Furthermore, a comparison of initial add-on therapy with DAPA plus SAXA with commonly used add-on therapy is useful for informing future treatment guidelines. However, beyond the scope of this manuscript, further analyses should be undertaken to establish whether there is an interaction between diabetes duration and treatment efficacy and durability.
In conclusion, the treatment strategy of triple therapy with the early combination of DAPA plus SAXA add-on to MET was well tolerated and resulted in significantly improved and long-term sustained glycaemic control and weight loss, without increasing the risk of hypoglycaemia, compared with the usual approach of adding only SITA to MET therapy in patients with inadequately controlled type 2 diabetes. These results suggest that, when MET alone becomes inadequate to control HbA1c, a strategy of early intensification with triple therapy using a combination of DAPA plus SAXA may result in better, more durable and welltolerated glycaemic control than adding only a single drug (SITA) as a dual combination therapy in patients with high HbA1c levels.
